What is the study drug?
The study drug (MET642) is designed to decrease inflammation, scarring, and fat build-up in the liver. It is a tablet taken by mouth once daily.
The study drug is investigational, which means it has not been approved by the Food and Drug Administration (FDA) or any other regulatory agency for use outside of clinical research studies.
Have other people taken the study drug?
Yes. Investigational drugs go through several phases of clinical research. This study drug has been tested in a Phase 1 study to make sure it is safe for humans.
The NASH-FXR study is now in Phase 2, which means it is testing if the study drug is safe and helpful for people with NASH.